3 enrolling by invitation. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Enrolling by invitation 3 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Efficacy of Elixirium Thymi Compositum in the Treatment of Acute Bronchitis in Pediatric Patients Elixirium thymi compositum (FoNo VIII.), Elixirium thymi compositum (FoNo VIII.) placebo - Acute Bronchitis | Phase 4 | Enrolling by invitation | Semmelweis University | 56 | 2025-07-01 | 2025-06-26 |
Asthma (2) · Pulmonary Eosinophilia (2) · Bronchitis (1) · Churg-Strauss Syndrome (1)
Bronchial Diseases (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Eosinophilia (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hypereosinophilic Syndrome (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Leukocyte Disorders (2) · Respiratory Hypersensitivity (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1)
Injections (1) · benralizumab (1) · mepolizumab (1)
Azienda Ospedaliero Universitaria di Cagliari (1) · Endeavor Health (1) · Semmelweis University (1)
Hungary (1) · Italy (1) · United States (1)
2025 (1)